pharma Β· Ulcerative colitis Β· central nervous system (CNS) lymphomas Β· RANI
Rani Therapeutics Holdings
Rani Therapeutics Holdings clinical programs β 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- San Jose, USA
- Founded
- 2012
- Employees
- 99
- Programs
- 7
- Drugs
- 12
- Patents
- 148
Rani Therapeutics Holdings projects
6 ClinicalTrials.gov programs sponsored by Rani Therapeutics Holdings.
Rani Therapeutics Holdings has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
GRT-1C101
Rani Therapeutics Holdings
Ulcerative colitis
1 trial -
GRT-1C102
Rani Therapeutics Holdings
Ulcerative colitis
1 trial -
RT-102 (80 ΞΌg)
Rani Therapeutics Holdings
Healthy Volunteers
1 trial -
RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity
Rani Therapeutics Holdings
Obesity
1 trial -
RaniPill capsule containing octreotide
Rani Therapeutics Holdings
Healthy Volunteers
1 trial -
Stelara
Rani Therapeutics Holdings
Healthy Volunteers
1 trial
Frequently asked questions
How many clinical projects does Rani Therapeutics Holdings have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.